Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 14/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL176824 | 0.83 | SLC22A12 (0.53) | SLC22A12PLA2G2A | |
| SCHEMBL176885 | 0.82 | SLC22A12 (0.52) | SLC22A12PLA2G2A | |
| SCHEMBL11975932 | 0.82 | SLC22A12 (0.70) | SLC22A12 | |
| SCHEMBL1554013 | 0.82 | SLC22A12 (0.73) | SLC22A12POLBMEN1KMT2A | |
| SCHEMBL13777341 | 0.81 | L3MBTL1 (0.62) | L3MBTL1POLBKDM4EMEN1KMT2A | |
| SCHEMBL176993 | 0.81 | SLC16A3 (0.46) | SLC22A12PLA2G2A | |
| SCHEMBL8572377 | 0.81 | SLC22A12 (0.61) | SLC22A12POLBMEN1KMT2A | |
| SCHEMBL1120899 | 0.80 | PDE5A (0.58) | SLC22A12L3MBTL1POLBKDM4EPLA2G2A | |
| SCHEMBL18853871 | 0.80 | ESR1 (0.63) | SLC22A12 | |
| SCHEMBL4029316 | 0.79 | ESR1 (0.67) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| US-20120225909-A1 | INDAZOLE ANALOG | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-09-06 | — | — | US | disclosed |
| EP-2484668-A1 | INDAZOLE ANALOGUE | Asahi Kasei Pharma Corporation (JP) | 2012-08-08 | — | — | EP | disclosed |
| CN-102171192-A | Indazole compounds | ASAHI KASEI PHARMA CORP | 2011-08-31 | — | — | CN | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| US-8008506-B2 | Indazole compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2011-08-30 | — | — | US | disclosed |
| EP-2345644-A1 | INDAZOLE COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2011-07-20 | — | — | EP | disclosed |
| EP-1935882-B1 | Bicyclic compounds | ASAHI KASEI PHARMA CORP (JP) | 2011-02-09 | — | — | EP | disclosed |
| US-7511069-B2 | Indazole compounds as β3 andrenoceptor agonist | ASAHI PHARMA CORPORATION (JP) | 2009-03-31 | — | — | US | disclosed |
| EP-1447400-B1 | BICYCLIC COMPOUND | ASAHI KASEI PHARMA CORP (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1935882-A1 | Bicyclic compounds | Asahi Kasei Pharma Corporation (JP) | 2008-06-25 | — | — | EP | disclosed |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | ASHI KASEI PHARMA CORPORATION (JP) | 2008-03-27 | — | — | US | disclosed |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ASAHI KASEI PHARMA CORPORATION (JP) | 2008-01-17 | — | — | US | disclosed |
| CN-100347158-C | Bicyclic compounds | ASAHI CHEMICAL IND (JP) | 2007-11-07 | — | — | CN | disclosed |
| US-7271190-B2 | Indazole compounds as β3 adrenoceptor agonist | ASAHI KASEI PHARMA CORPORATION (JP) | 2007-09-18 | — | — | US | disclosed |
| CN-1606544-A | Bicyclic compounds | ASAHI CHEMICAL IND (JP) | 2005-04-13 | — | — | CN | disclosed |
| US-20050020602-A1 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1447400-A1 | BICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225909-A1 | INDAZOLE ANALOG | ADRB3, ADRB1, ADRB2 | SLC22A12 2079/4885L3MBTL1 3039/4885POLB 2992/4885 |
| US-20050020602-A1 | Bicyclic compound | GOT1, H1-0, HSD11B1 | SLC22A12 2162/4885L3MBTL1 1485/4885POLB 2714/4885 |
| US-20080076815-A1 | Indole compounds as B3 androceptor agonist | OPRL1, NPBWR1, NPY4R | SLC22A12 1955/4885L3MBTL1 3103/4885POLB 4384/4885 |
| US-20080015242-A1 | INDOLE COMPOUNDS AS BETA3 ANDROCEPTOR AGONIST | ADRB3, ADRB2, OPRD1 | SLC22A12 2664/4885L3MBTL1 3251/4885POLB 4246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.